/Edwards%20Lifesciences%20Corp%20Irvine%2C%20Ca%20campus-by%20Steve%20Cukrov%20via%20Shutterstock.jpg)
With a market cap of $48.4 billion, Edwards Lifesciences Corporation (EW) is a global medical technology company specializing in innovative products for structural heart disease and critical care monitoring. Founded in 1958, the California-based company is recognized as a pioneer and market leader in transcatheter heart valve therapies. It also develops surgical heart valves, repair products for mitral and tricuspid valve disease, and advanced hemodynamic monitoring systems used in intensive care and operating rooms.
Shares of the company have outperformed the broader market over the past 52 weeks. EW stock has increased 27% over this time frame, while the broader S&P 500 Index ($SPX) has gained 14%. However, shares of the company have risen 13.6% on a YTD basis, compared to SPX's 16.2% return.
